The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
Inlyta [package insert].New York: Pfizer Labs; January 2012.
2.
RugoH.S.HerbstR.S.LiuG.Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol.2005; 23(24): 5474–5483.
3.
RiniB.I.WildingG.HudesG.Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol.2009; 27(27): 4462–4468.
4.
SchillerJ.H.LarsonT.OuS.H.I.Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol.2009; 27(23): 3836–3841.
5.
CohenE.E.W.RosenL.S.VokesE.E.Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol.2008; 26(29): 4708–4713.
6.
RixeO.BukowskiR.M.MichaelsonM.D.Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol.2007; 8(11): 975–984.
7.
RiniB.I.EscudierB.TomczakP.Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase III trial. Lancet.2011; 378(9807): 1931–1939.
8.
Erivedge [package insert].South San Francisco, CA: Genentech USA, Inc; January 2012.
9.
LoRussoP.M.JimenoA.DyG.Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res.2011; 17(17): 5774–5782.
10.
LoRussoP.M.RudinC.M.ReddyJ.C.Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res.2011; 17(8): 2502–2511.
11.
Von HoffD.D.LoRussoP.M.RudinC.M.Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med.2009; 361(12): 1164–1172.
12.
SekulicA.MigdenM.R.OroA.E.A pivotal study evaluating efficacy and safety of the hedgehog pathway inhibitor (HPI) vismodegib (GDC-0449) in patients with locally advanced (Ia) or metastatic (m) basal cell carcinoma (BCC) [abstract]. Melanoma Res.2011; 21: e9. Abstract CO14.
